Using the activity risk scale to help plan your activities

Using the activity risk scale to help plan your activities

For more information about the risks of certain activities, read the following publication: Anderson A, Forsyth A. Playing it Safe. New York, NY: National Hemophilia Foundation; 2005. 

No matter how in shape you are and no matter what skill level you have, various activities carry risks.

Individuals with von Willebrand disease can be at an increased risk when playing sports or exercising. Understanding what the risks are can help you make good choices about your participation in certain activities.

Select a risk level to see how certain activities rank on a scale from 1 (safe) to 3 (dangerous).

It is important to note that Level 1, Level 1.5, and Level 2 indicate that the health benefits of these particular activities may outweigh the associated risks. All sports that are rated as Level 2.5 and Level 3 are dangerous and are not recommended for people with bleeding disorders.

1
Safe
1.5
Safe to
Moderate
2
Moderate
2.5
Moderately
Dangerous
3
Dangerous
Very Low Risk Low Risk Medium Risk High Risk Very High Risk
Aquatics
Archery
Fishing
Frisbee
Golf
Hiking
Snorkeling
Stationary bike
Swimming
Walking
Bicycling
Body sculpting
Circuit training
Frisbee golf
Pilates
Spinning
Treadmill
Weightlifting/
resistance training
Aerobics
Bowling
Cardio kickboxing
Dance
Rock climbing
(indoor)
Roller-skating
Running/jogging
Stepper
Tennis
Yoga
Baseball
Basketball
Cheerleading
Horseback riding
Kayaking
Mountain biking
River rafting
Soccer
Softball
Surfing
Boxing
Football
Hockey (all)
Lacrosse
Motorcycling/
motocross racing
Powerlifting
Rock climbing
(natural)
Rugby
Scooter
(motorized)
Wrestling

Indications

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery
Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.